middl
east
respiratori
syndrom
mer
sever
respiratori
infect
caus
novel
beta
coronaviru
merscov
symptom
mer
includ
fever
chill
cough
short
breath
gastrointestin
symptom
expector
wheez
chest
pain
hemoptysi
sore
throat
headach
myalgia
abdomin
pain
vomit
diarrhea
also
caus
death
sever
case
caus
pathogen
mer
transmit
via
mode
animaltohuman
intrafamili
healthcareassoci
travelrel
case
occur
south
korea
hereaft
korea
predominantli
caus
healthcareassoci
transmiss
follow
intrafamili
transmiss
accord
data
report
world
health
organ
rate
asymptomat
mild
infect
saudi
arabia
unit
arab
emir
islam
republ
iran
april
june
saudi
arabia
june
howev
oboho
et
al
report
initi
report
asymptomat
patient
least
symptom
korea
among
confirm
case
asymptomat
case
detect
among
healthcar
worker
via
screen
test
serolog
studi
use
indirect
immunofluoresc
test
healthcar
worker
mersaffect
hospit
posit
result
howev
report
publish
regard
asymptomat
infect
rate
among
nonhealthcar
worker
korea
consider
chanc
humantohuman
transmiss
well
direct
infect
via
dromedari
camel
therefor
necessari
identifi
rate
asymptomat
mer
infect
healthcar
worker
nonhealthcar
worker
survey
conduct
august
februari
last
mer
case
diagnos
juli
base
databas
quarantin
individu
provid
depart
epidemiolog
investig
korea
center
diseas
control
prevent
kcdc
individu
region
major
gyeonggi
chungcheong
jeonbuk
select
individu
whose
mer
statu
diagnos
posit
use
polymeras
chain
reaction
test
exclud
analysi
studi
quarantin
individu
resid
live
major
mer
outbreak
region
select
individu
call
request
particip
studi
made
individu
accord
priorit
group
total
individu
ultim
particip
studi
figur
refus
particip
describ
anoth
studi
studi
individu
priorit
group
accord
transmiss
intens
mer
case
expos
follow
contact
superspread
event
individu
infect
contact
spreader
infect
individu
contact
nonspread
select
studi
subject
accord
priorit
group
select
rate
respect
also
categor
subject
accord
exposur
intens
ie
statu
expos
mer
case
follow
inpati
outpati
mersaffect
hospit
cohabit
famili
member
paid
caregiv
mer
case
visitor
hospit
mer
case
healthcar
worker
employ
mersaffect
hospit
colleagu
mer
case
select
subject
categori
famili
patient
visitor
tabl
individu
consent
particip
studi
telephon
call
gave
written
consent
time
studi
initi
underw
survey
local
public
health
center
particip
respond
questionnair
exposur
provid
blood
sampl
follow
first
serolog
test
enzymelink
immunospecif
assay
elisa
posit
borderlin
case
test
use
immunofluoresc
assay
ifa
plaqu
reduct
neutral
antibodi
test
prnt
merscov
antibodi
level
sera
collect
contact
measur
use
recombin
proteinco
human
antimerscov
immunoglobulin
g
igg
elisa
kit
euroimmun
luebeck
germani
use
accord
manufactur
protocol
result
test
sampl
determin
calcul
ratio
optic
densiti
od
valu
sampl
od
valu
calibr
ratio
consid
posit
ratio
consid
borderlin
ratio
consid
neg
ifa
slide
coat
merscov
noninfect
infect
vero
cell
serum
sampl
dilut
phosphatebuff
salin
pb
transfer
ifa
slide
incub
minut
humidifi
chamber
ifa
slide
wash
time
pbst
minut
incub
fluorescein
isothiocyanateconjug
rabbit
antihuman
igg
abcam
cambridg
usa
dilut
minut
humidifi
chamber
wash
time
pbst
minut
slide
embed
mount
fluid
top
cover
glass
observ
fluoresc
microscop
neutral
antibodi
serum
sampl
measur
prnt
prnt
procedur
perform
follow
brief
dilut
sera
heatinactiv
minut
heatinactiv
sera
dilut
serial
equal
volum
viru
ad
volum
serum
dilut
mixtur
incub
hour
mixtur
ad
well
plate
cultur
vero
cell
plate
incub
minut
ml
carboxymethylcellulos
overlay
medium
ad
incub
day
cell
stain
perform
crystal
violet
titer
neutral
antibodi
calcul
use
formula
describ
previous
titer
interpret
posit
sera
posit
borderlin
reaction
elisa
test
ifa
prnt
assay
confirm
case
posit
result
assay
consid
antim
posit
studi
receiv
approv
bioethic
committe
kcdc
institut
review
board
nation
cancer
center
ncc
inform
consent
obtain
studi
particip
parent
legal
guardian
children
among
select
individu
respons
rate
contact
superspread
event
individu
infect
contact
spreader
infect
individu
contact
nonspread
respect
accord
statu
expos
mer
case
highest
respons
rate
found
healthcar
worker
famili
member
follow
visitor
colleagu
patient
tabl
seroposit
rate
use
elisa
patient
healthcar
worker
overal
among
elisaposit
individu
contact
superspread
event
patient
zero
case
whoinfect
individu
contact
spreader
case
infect
individu
contact
nonspread
case
among
elisaposit
individu
ifaposit
prntposit
therefor
confirm
rate
asymptomat
mer
infect
patient
confid
interv
overal
tabl
confirm
asymptomat
case
patient
zero
secondari
mer
patient
hospit
floor
hospit
time
asymptomat
case
quarantin
home
week
discharg
case
underli
diseas
includ
hypertens
angina
degen
arthriti
case
report
fever
cough
myalgia
gastrointestin
symptom
hospit
quarantin
tabl
limit
inform
exist
regard
merscov
seropreval
among
popul
confirm
mer
case
saudi
arabian
data
show
seropreval
merscov
igg
among
gener
popul
suggest
number
case
asymptomat
mild
infect
may
present
gener
popul
despit
high
preval
confirm
mer
case
outbreak
mer
korea
rate
asymptomat
infect
lower
expect
rate
asymptomat
infect
confirm
use
ifa
prnt
present
studi
contact
patient
result
markedli
lower
rate
among
healthcar
worker
among
healthcar
worker
mersaffect
hospit
korea
moreov
rate
asymptomat
mild
infect
saudi
arabia
unit
arab
emir
islam
republ
iran
approxim
confirm
asymptomat
case
present
studi
patient
hospit
confirm
mer
case
unlik
previou
studi
neither
intrafamili
infect
pediatr
infect
low
rate
asymptomat
infect
korea
attribut
differ
transmiss
pathway
mer
infect
compar
middl
east
korea
mer
case
healthcareassoci
infect
none
anim
low
asymptomat
infect
rate
also
attribut
extens
epidemiolog
investig
conduct
korea
includ
close
monitor
contact
mer
patient
help
identifi
almost
mer
patient
may
also
attribut
promot
proactiv
identif
patient
via
mass
media
establish
commun
network
govern
lead
voluntari
report
peopl
activ
quarantin
countermeasur
public
health
crisi
elisa
appropri
screen
tool
sensit
ifa
howev
may
crossreact
season
human
coronaviru
antibodi
spike
proteinspecif
ifa
requir
confirm
prnt
definit
test
elisa
ifa
inconclus
result
elisaposit
result
posit
neutral
assay
studi
patient
borderlin
posit
elisa
result
also
posit
result
prnt
therefor
result
obtain
studi
accur
elisa
ifa
prnt
use
previou
studi
predict
pandem
potenti
merscov
howev
indic
risk
abat
prerequisit
reduc
risk
includ
improv
surveil
activ
contact
trace
initi
anim
host
search
outbreak
korea
mer
classifi
notifi
infecti
diseas
subject
surveil
sinc
mer
import
diseas
korea
recommend
precaut
taken
travel
time
return
travel
incub
period
consid
studi
show
low
seroposit
popul
individu
quarantin
due
contact
mer
case
howev
possibl
seroposit
rate
underestim
follow
reason
firstli
particip
present
studi
mostli
nonhealthcar
worker
rel
healthi
thu
risk
infect
low
secondli
overal
particip
rate
wherea
patient
group
higher
risk
infect
moreov
survey
quarantin
individu
therefor
actual
rate
asymptomat
infect
may
higher
report
present
studi
lastli
present
studi
may
conduct
late
previou
studi
merscov
elisa
result
indic
antibodi
respons
highest
week
symptom
onset
although
report
analyz
durat
antibodi
presenc
mer
patient
regardless
symptom
recent
studi
sever
acut
respiratori
syndrom
mer
report
antibodi
patient
persist
year
infect
blood
sampl
serolog
test
studi
perform
contact
octob
decemb
exposur
confirm
case
occur
may
june
gap
month
thu
loss
merscov
antibodi
titer
could
taken
place
despit
actual
asymptomat
infect
therefor
actual
rate
asymptomat
infect
may
higher
rate
present
report
conclus
among
contact
nonhealthcar
worker
patient
mersaffect
hospit
asymptomat
merscov
infect
understand
new
emerg
infecti
diseas
mer
intens
epidemiolog
research
need
includ
analysi
asymptomat
infect
